{"name":"Bright Minds Biosciences Pty Ltd","slug":"bright-minds-biosciences-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BMB-101","genericName":"BMB-101","slug":"bmb-101","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"}]}],"pipeline":[{"name":"BMB-101","genericName":"BMB-101","slug":"bmb-101","phase":"phase_2","mechanism":"BMB-101 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOR2ZuRlVJSllyY0x2T3VjemxmWmFDenYzMXJTVFhnOHZzX1BPSDBydXJkekNydGtxcWNWNmRKblRfenI5SlEwb2VjLTBpeXpVS2hlVXhKMHhWZHg5UlZlUlBhTTNiUEdRLU1pZ2FCc042XzRDTHdIQVRCRXVZb3pqUnZEMnoxOFFfcjZVZnRMOU5Fa2luWFB0Z28xUlk3Tk5ZX01rSFdfRzJndUR1OE00ZFF1Zw?oc=5","date":"2026-04-07","type":"pipeline","source":"MarketBeat","summary":"Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Here's Why - MarketBeat","headline":"Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSU1nZ0VqM3RfRGppZVpmaW9IaWEtSXFzMDVLc3QybFZPQnMyb2szcm0xeDB2UGNJeVQ1dUpEMlU4Sy0tamtsQ0lJV0Z4VGc4WFdkcjJTN0VJa1RhRXB6YWNNempmZURoRE95Y05ocktOeEFOeHdtcHkwT3d5NnYwTmNDNjNDVUFERkRNTk9BOVp6cU1SSmk0YUNKQQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key - openPR.com","headline":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNbWN2c2FZMW4xVTNlb0lLS2ZEV2t2TmVfRko5U2NuY21NX2t4M1Fzd0VuVVl1VG9BS1o0ektzZHBRTTVmNEU5LXc4YkMyZE5wbjhzckU5RmhzQzdnQmM5SmtVR21YWXI5TU1hVEFuNGI5bFFTcjFfejZNSUFuRmNickFrdnVpNkN3bXlnMnBMa2lsYUh6b3NsZXZNRlNBbU9rcXR0X0NJLUdXV2JQa1NQWDJzcGtLemxFV1ZHVVR3MFpMcnlIRmpKdEp1RlJJb1lHbWhqT0JPYTVrbkI2OENvWW15QV9LQ3hUTmc?oc=5","date":"2025-12-16","type":"trial","source":"Proactive financial news","summary":"Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials - Proactive financial news","headline":"Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-01","type":"pipeline","source":"simplywall.st","summary":"We Think Bright Minds Biosciences (CSE:DRUG) Can Easily Afford To Drive Business Growth - simplywall.st","headline":"We Think Bright Minds Biosciences (CSE:DRUG) Can Easily Afford To Drive Business Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNelhGRWdNOUpyWkFNSHZzMml5MHFvYnpHMmVhN0RjRmZ6UW5WR0hMeTM2SG91enFaNUk0ODRmekxuQWxjMHo1eHRpRlR4ZXZLNFpIOEkzQTRMMnNDaWNiUXQtMFFON2VFSWRJUUp4MXUySklNUThyRXlVSlYyOEVyR1hENnBUT1gtQmtGTDE1clFDNmhYWWNGTG1VSVFWUXl1cnBSNW9Rdkdpa0FFU3RsWlZXVVVJc2VoOFZRZ1lPekVyTUtLZGNGM0cxMlZaQkstMFRzbkx5YVNHdzJmbm1qOEdKWFhQQ3dDNWFCZXJYS2JOUjhCM0Z2OVV0Z3NocUpVRTJSY3BKSzVoaVowOWpkZzROSXV3dkFVRm9EVVlxNmNPVmM?oc=5","date":"2025-04-08","type":"pipeline","source":"GlobeNewswire","summary":"Developmental and Epileptic Encephalopathies Market to - GlobeNewswire","headline":"Developmental and Epileptic Encephalopathies Market to","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}